Sulfinpyrazone after Myocardial Infarction

To the Editor: I should be obliged if the authors of the report on the Anturane Reinfarction Trial in the February 9 issue of the Journal could clarify one particular point — namely, the percentage of patients who continued smoking, on sulfinpyrazone, as compared to placebo. In the article, mention is only made for smoking before infarction, in which the two groups were comparable. Were any separate analyses done comparing groups of patients in the placebo and sulfinpyrazone groups, correcting for number of cigarettes smoked?.